PLRZ ▼ -0.1% - Polyrizon Ltd. $PLRZ - Polyrizon Enrolls First Patient in U.S. Clinical Study of NASARIX (PL-14) Allergy Blocker Polyrizon Ltd. shares fell 0.1% today following news that the company has enrolled its first patient in a U.S. clinical study of NASARIX (PL-14), an allergy blocker treatment. The modest decline suggests investors may be taking profits on the enrollment milestone or awaiting further clinical progress before committing additional capital. 22-SEP-2026 08:33 AM ET